CureVac Nears Final Chapter with BioNTech Acquisition and Index Removal
Veröffentlicht: 05.12.2025 um 10:20 Uhr, Redaktion boerse-global.de
The biotechnology firm CureVac is approaching its final days as a publicly traded company on the NASDAQ. The acquisition by competitor BioNTech is now virtually assured, with the overwhelming majority of shareholders having already tendered their shares. This corporate transition coincides with the stock’s imminent removal from a major market index, presenting specific considerations for remaining investors.
BioNTech reported on December 3 that approximately 184 million CureVac shares had been tendered, representing 81.74 percent of the share capital. This figure comfortably surpasses the minimum acceptance threshold for the takeover to proceed. The offer remains open until 0:01 a.m. ET on December 18, 2025, allowing remaining holders to exchange their Read more...
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
